bject Code :5PS02DRI1 Summer Examination-2014	Date: 23/06/2014
bject Name: Drug Regulatory Aspects & IPR ranch/Semester:- M.Pharm/II	Time:02:00 To 5:00
amination: Regular	Time:02:00 10 5:00
 structions:-) Attempt all Questions of both sections in same answer book / Supplementary) Use of Programmable calculator & any other electronic instrument is prohibited.) Instructions written on main answer Book are strictly to be obeyed.)Draw neat diagrams & figures (If necessary) at right places) Assume suitable & Perfect data if needed 	
SECTION - I	
-1 Define the term :	(7)
EMEA ii)Holder iii) TRIPS iv)Copyright v)Green book	
)CDER vii)Appellate Board	
-2 a) Write a note on Drug Master File(DMF).	(5)
a) Write a note on Drug Master File(DMF).b) Define CTD & eCTD. Explain modules of CTD.	(5) (5)
c) What is TGA ? Discuss TGA's risk management approach.	(3)
OR	(T)
-2 a) Describe the patent rule 2003.	(5)
b) Mention the goals of NDA. Discuss the general requirements for filing NDA	
 c) Which medicines are not accepted as generic by ANVISA. -3 	(4)
a) Give an overview of websites that provide free information on patent.	(7)
b) Write a note on Paris convention.OR	(7)
a) Write a note on Uruguay TRIPS	(7)
b) Discuss in detail guideline for Japan	(7)
-4 Define the term :	(7)
	Blue book
-5	
a) Discuss the phases of investigation in context to IND.	(5)
b) Write a note on Hatchwaxman amendments.	(5)
c) Discuss the benefits of IPR.	(4)
-5 OR	
a) Explain centralized and decentralized procedure for registration at EMEA with	
	(5)
b) Write a short note on CDER.	(5)
c) Write a short note on ARTG. -6	(4)
a) Define the term invention. Write Explainatory note on non-patentable invent	ion. (7)
b) Discuss in detail Orange Book?	(7)
OR	
-6	
	(7)
a) Write a note on CDSCO and DTAB.b) Discuss roles of CBER in USFDA.	(7)

Page 1 of 1